secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2022-12-20T23:59:59+00:00
Accession:  0001193125-22-309181
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara Biotherapeutics sells portion of Ebvallo royalty rights to HCR for $31M cash
--------------------------------------------------------------------------------

- HCR to pay $31M within 15 business days after Ebvallo European approval for rights to future royalties and milestones.
- HCR receives tiered royalties (mid-single to significant double digits) and part of milestones from Pierre Fabre.
- Total return to HCR capped at 185%–250% of investment, dependent on timing.
- Atara retains remaining royalty and milestone interests under the Commercialization Agreement with Pierre Fabre.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312522309181/0001193125-22-309181-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312522309181/d392249d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-309181

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer